EU and US could reach trade deal this weekend - Reuters
PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY) announced Tuesday that its Board of Directors has declared a quarterly dividend of $0.62 per share on the company’s common stock, representing an attractive 5.1% yield. The dividend will be payable on August 1, 2025, to stockholders of record as of July 3, 2025. The company has maintained dividend payments for 55 consecutive years, demonstrating its commitment to shareholder returns.
The pharmaceutical company also declared a quarterly dividend of $0.50 per share on its $2.00 convertible preferred stock, which will be paid on September 2, 2025, to stockholders of record at the close of business on August 5, 2025.
This announcement maintains Bristol Myers Squibb’s consistent dividend payment schedule for shareholders. The company, which focuses on developing medicines for serious diseases, made the declaration through a press release statement.
Bristol Myers Squibb is headquartered in Princeton, New Jersey, and trades on the New York Stock Exchange under the ticker symbol BMY.
In other recent news, Bristol Myers Squibb reported significant clinical trial results for its CAR T cell therapy, lisocabtagene maraleucel, achieving a 95.5% response rate in patients with relapsed or refractory marginal zone lymphoma. The TRANSCEND FL study further highlighted that 62.1% of patients reached complete response, with a majority maintaining their response over a 24-month period. Additionally, Bristol Myers Squibb announced positive outcomes for its psoriatic arthritis drug, Sotyktu, in a Phase 3 trial, where 54.2% of patients experienced at least a 20% improvement in symptoms.
Meanwhile, the company is set to acquire rights to the prostate cancer drug OncoACP3 from Philochem AG, in a deal valued up to $1.35 billion. This acquisition aims to enhance Bristol Myers Squibb’s position in the radiopharmaceuticals market. In other developments, Cantor Fitzgerald maintained its neutral rating on Bristol Myers Squibb, highlighting upcoming Alzheimer’s treatment data as a key catalyst for the company. Furthermore, Bristol Myers Squibb presented new data from its targeted protein degradation platform at the European Hematology Association Annual Congress, showcasing investigational agents for multiple myeloma and non-Hodgkin lymphoma. These diverse advancements underscore Bristol Myers Squibb’s continued efforts in expanding its therapeutic portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.